Sana Biotechnology, Inc. (SANA) stock
SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.74−0.11 (-5.95%)
Close on Nov 19, 2026Market cap $520.89MP/E –Yield –
Sana Biotechnology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sana Biotechnology's operating income for the twelve months ending Jun 30, 2026 was -$218.75M. For fiscal 2025 it was -$250.32M. The highest annual figure on record is -$141.15M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$250.32M | – |
| FY2024 | Dec 31, 2024 | -$272.72M | – |
| FY2023 | Dec 31, 2023 | -$293.14M | – |
| FY2022 | Dec 31, 2022 | -$272.56M | – |
| FY2021 | Dec 31, 2021 | -$356.91M | – |
| FY2020 | Dec 31, 2020 | -$286.15M | – |
| FY2019 | Dec 31, 2019 | -$141.15M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$65.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$48.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$61.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$43.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$94.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$50.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$50.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$61.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$49.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$110.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$90.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$116.29M | – |
| Q1 FY2023 | Mar 31, 2023 | -$84.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$81.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$86.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$72.90M | -493.0% |
| Q1 FY2022 | Mar 31, 2022 | -$31.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$111.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$83.43M | – |
| Q2 FY2021 | Jun 30, 2021 | $18.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$180.75M | – |
| Q4 FY2020 | Dec 31, 2020 | -$113.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$51.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$87.91M | – |
| Q1 FY2020 | Mar 31, 2020 | -$33.28M | – |
See a number that looks wrong?